Axsome Therapeut Stock Price, News & Analysis

Axsome Therapeutics (NASDAQ: AXSM) announced five abstracts to be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting from April 22-27, showcasing new findings from the SHARP study. This study involved 59 patients suffering from excessive daytime sleepiness (EDS) related to obstructive sleep apnea (OSA) and cognitive impairment. Results indicated that solriamfetol, Axsome's treatment, demonstrated a potential clinical benefit, suggesting it as a viable option for EDS management in OSA patients. Presentations will also cover solriamfetol's pharmacological effects and ongoing real-world studies. Key presentations include results demonstrating solriamfetol's efficacy and ongoing clinical trials for migraine treatment with AXS-07.

Axsome Therapeutics (NASDAQ: AXSM) announced that CEO Herriot Tabuteau will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 1:30 p.m. ET. This event will provide insights into the company's novel therapies for central nervous system disorders. Interested parties can access a live webcast and an archive of the discussion on the Investors section of Axsome's website. The company focuses on developing innovative treatments for CNS conditions, aiming to enhance patient care. Forward-looking statements in the release highlight potential future developments, including risks and uncertainties surrounding product success and regulatory approvals.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) has announced a conference call scheduled for May 8, 2023, at 8:00 a.m. Eastern Time to discuss its financial results for the first quarter of 2023. This call will be held prior to the opening of U.S. financial markets and will also provide a business update. Interested participants can access the live conference call by dialing (877) 405-1239 or through a webcast on the company’s website. Axsome specializes in developing therapies for central nervous system (CNS) disorders and is focused on transforming treatment options with novel approaches. The company highlights its commitment to improve patients' lives by offering new therapeutic avenues for physicians.

Axsome Therapeutics (NASDAQ: AXSM) announced CEO Herriot Tabuteau will join a fireside chat at Cowen's 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston. The event aims to showcase Axsome's innovative therapies for CNS disorders. Interested parties can access a live webcast of the discussion through the company's website.

Axsome focuses on developing novel treatment options for CNS conditions with limited remedies available. The company emphasizes its commitment to improving patient care and advancing drug development.

Axsome Therapeutics reported fourth quarter 2022 net product sales of $24.4 million, with Auvelity generating $5.2 million and Sunosi $19.2 million. The company launched Auvelity on October 19, 2022, bolstered by a new licensing agreement for Sunosi in Europe, worth $66 million upfront and potential milestones of $101 million. Net loss for Q4 was $61.2 million or $(1.41) per share, compared to a loss of $34 million in Q4 2021. Despite increased operational costs, Axsome boasts over $300 million in cash, positioning itself well for future growth amidst ongoing R&D for CNS disorders.